Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
ESMO Congress 2025
ACS Clinical Congress 2025
2025 ASCO Quality Care Symposium
2025 ASTRO Annual Meeting
2025 Debates and Didactics in Hematology and Oncology
Calendar
View All
Topics
AI in Oncology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Conquer Cancer Foundation
November 10, 2018
Advertisement
Advertisement
Advertisement
Nov
14
Today In Oncology
FDA Approves Ziftomenib for NPM1-Positive AML
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
Transfusion Access Prioritized Over Routine Hospice Services Among Patients With Blood Cancers
View More
Advertisement
